The United States Soliris Market size is reached a valuation of USD xx.x Billion in 2023, with projections to achieve USD xx.x Billion by 2031, demonstrating a compound annual growth rate (CAGR) of xx.x% from 2024 to 2031.
United States Soliris Market By Application
- Rare Blood Disorders
- Neurological Disorders
- Hematological Disorders
- Rheumatological Disorders
- Transplant Rejection
The United States market for Soliris (eculizumab) by application exhibits diverse segmentation across several key areas. Rare Blood Disorders represent a significant segment, encompassing conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Neurological Disorders constitute another crucial application segment, focusing on conditions like myasthenia gravis (MG) where Soliris has shown efficacy. Additionally, Hematological Disorders form a distinct segment, addressing disorders like cold agglutinin disease (CAD). Rheumatological Disorders, including conditions like neuromyelitis optica spectrum disorder (NMOSD), also contribute substantially to the market. Furthermore, Soliris is utilized in addressing Transplant Rejection, particularly in the prevention and treatment phases post-transplantation.